Trial Profile
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2-Nonoverexpressing Metastatic Breast Cancers.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Carboplatin
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Biomarker; Therapeutic Use
- 15 Mar 2017 Status changed from active, no longer recruiting to completed.
- 15 Mar 2017 Status changed from active, no longer recruiting to completed.
- 15 Mar 2017 Status changed from active, no longer recruiting to completed.